[go: up one dir, main page]

WO1999002531A1 - Procede de synthetisation d'intermediaires de carbapenem a chaine laterale - Google Patents

Procede de synthetisation d'intermediaires de carbapenem a chaine laterale Download PDF

Info

Publication number
WO1999002531A1
WO1999002531A1 PCT/US1998/013738 US9813738W WO9902531A1 WO 1999002531 A1 WO1999002531 A1 WO 1999002531A1 US 9813738 W US9813738 W US 9813738W WO 9902531 A1 WO9902531 A1 WO 9902531A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
accordance
formula
produce
reacted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/013738
Other languages
English (en)
Inventor
Karel M. J. Brands
John M. Williams
Ulf H. Dolling
Ronald B. Jobson
Anthony J. Davies
Ian F. Cottrell
Mark Cameron
Michael S. Ashwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9810184.3A external-priority patent/GB9810184D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to AU82821/98A priority Critical patent/AU731586B2/en
Priority to CA002294342A priority patent/CA2294342C/fr
Priority to JP50875599A priority patent/JP2002504156A/ja
Priority to EP98933069A priority patent/EP1019411A4/fr
Publication of WO1999002531A1 publication Critical patent/WO1999002531A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings

Definitions

  • the present invention relates to the synthesis of carbapenem side chains, and in particular, to side chains or portions thereof containing a pyrrolidine group, which is bonded to the carbapenem nucleus through a thioether linkage.
  • the pyrrolidine is a portion of the side chain, and is substituted at the two position with any of a variety of substituents.
  • EP 551 993 Al published on July 21, 1993 relates to a synthesis which utilizes active esterifying agents and base, followed by treatment with hydrogen sulfide, or an alkali metal salt of hydrogen sulfide, and base.
  • the present invention is an improvement over these other processes, utilizing a sulfide source which surprisingly improves the process when commercial quantities are synthesized.
  • R! and R2 are independently selected from hydrogen, aryl and heteroaryl, said aryl and heteroaryl groups being unsubstituted or substituted with from 1-3 groups selected from the group consisting of: Cl-4 alkyl, Cl_4 alkoxy, Cl-4 alkyl thio, halo, hydroxy, CO2H, CO2CI-4 alkyl, NH 2 , NHCl-4 alkyl, N(Ci-4 alkyl)2, SO3H, CN, NHC(0)C M alkyl, S0 2 NH 2 , SO2C1-4 alkyl, aryl and heteroaryl;
  • Alkyl and the alkyl portions of substituent groups include monovalent hydrocarbon chains containing from 1-4 carbon atoms which are straight or branched as appropriate.
  • Aryl refers to 6-10 membered mono- and bicyclic ring systems, containing carbon atoms with alternating (resonating) double bonds.
  • Preferred aryl groups are phenyl and naphthyl.
  • Heteroaryl refers to aromatic 5-10 membered mono- and bicyclic ring systems, containing from 1-4 heteroatoms, O, S or N.
  • Preferred nitrogen containing monocyclic heteroaryl groups include pyridyl, pyrimidinyl, pyrazinyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl and 1, 2, 4-triazolyl.
  • Preferred heteroaryl groups containing oxygen as the only heterotom include furanyl.
  • Preferred heteroaryl groups containing sulfur as the only heterotom include thienyl.
  • Preferred bicyclic heteroaryl groups include benzthiazolyl, benzimidazolyl, quinolinyl and isoquinolinyl, indolyl and isoindolyl.
  • the aryl and heteroaryl groups may be substituted with 1-3 groups selected from the group consisting of: Ci-4 alkyl, Ci-4 alkoxy, C1.4 alkylthio, halo, hydroxy, CO2H, CO2C1-4 alkyl, NH 2 , NHC1-4 alkyl, N(C ⁇ _ 4 alkyl) 2 , NHC(0)Ci- 4 alkyl, SO3H, CN, SO2NH2, SO2C1-4 alkyl, aryl and heteroaryl.
  • Suitable protecting groups include the following without limitation: t-butylmethoxyphenylsilyl, t-butoxydiphenylsilyl, trimethylsilyl, triethylsilyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyl- oxycarbonyl, benzyloxycarbonyl, t-butyloxycarbonyl (t-BOC), 2,2,2- trichloroethyloxycarbonyl benzhydryl, o-nitrobenzyl, p-nitrobenzyl, 2-naphthylmethyl, allyl, 2-chloroallyl, benzyl, 2,2,2-trichloroethyl, trimethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, 2-(trimethyl- silyl)ethyl,
  • Preferred silyl protecting groups are trimethylsilyl and triethylsilyl.
  • Preferred carboxyl protecting groups are p-nitrobenzyl and allyl.
  • Preferred phosphoryl based protecting groups include diisopropylphosphoryl.
  • P represents a protecting group on the proline nitrogen atom.
  • P represents a member selected from the group consisting of: t-butylmethoxyphenylsilyl, t-butoxydiphenylsilyl, trimethylsilyl, triethylsilyl, o-nitrobenzyloxycarbonyl, p-nitro- benzyloxycarbonyl, benzyloxycarbonyl, t-butyloxycarbonyl (t-BOC), 2,2,2-trichloroethyloxycarbonyl benzhydryl, o-nitrobenzyl, p-nitrobenzyl, 2-naphthylmethyl, allyl, 2-chloroallyl, benzyl, 2,2,2-trichloroethyl, trimethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, 2-(trimethylsilyl) ethyl, phen
  • P represents a protecting group which is selected from the group consisting of: t-BOC, diisopropylphosphoryl and p-nitrobenzyloxycarbonyl.
  • P represents diisopropylphosphoryl.
  • Compound 2 used herein as a starting material is N protected trans-4-hydroxy-L-proline.
  • the 2-carboxyl group is activated using the compound diphenylphosphinic chloride, which is reacted with compound II in a solvent in the presence of excess base.
  • Solvents which are useful herein include dichloromethane, acetonitrile, toluene, fluorobenzene, tetrahydrofuran, or mixtures thereof.
  • Bases which are useful for this reaction include trialkylamines.
  • Preferred trialkylamines include diisopropylethylamine (DIPEA) and triethylamine.
  • diphenylphosphinic chloride which is about equimolar to the starting compound
  • the reaction between compound 2 and diphenylphosphinic chloride is typically run at reduced temperature, below about 0°C to as low as about -40°C.
  • the reaction temperature is maintained at about -10°C.
  • Compound 3, with the diphenylphosphinyloxycarbonyl group at position two is reacted with methanesulfonyl chloride (MsCl) to produce compound 4.
  • MsCl methanesulfonyl chloride
  • This reaction is conducted in a solvent, in the presence of a slight molar excess of pyridine, collidine, lutidine and the like, using a slight molar excess of MsCl.
  • This mesylation reaction may be conducted over about 1-4 hours, at a reduced temperature, e.g., about 0°C to as low as about -40°C.
  • the reaction temperature is maintained at about -10°C.
  • Compound 4 is thereafter combined with an alkali metal sulfide or non-alkali metal sulfide and water to form the thiolactone 1.
  • the reaction can be conducted at about -10°C to about room temperature.
  • the sulfide and water are added quickly, and the reaction is aged for several hours at ambient temperature.
  • alkali metal sulfide refers to the group I metal sulfides, such as the sulfides of sodium and potassium.
  • the alkali metal sulfide is Na 2 S.
  • non-alkali metal sulfides and “alkaline earth metals” are used interchangeably to include the group II alkaline earth metal sulfides selected from the group consisting of: magnesium, calcium and barium. Preferred are calcium and barium.
  • the preferred non-alkali metal sulfide most notably CaS, provides an unexpected advantage in that side products of the reaction have low solubility in water, and thus can be removed as a precipitate.
  • the amine HNR'R 2 is m-aminobenzoic acid.
  • the compound of formula 5 is reacted with an acid to produce a compound of formula 6:
  • compound 4' is reacted with a member selected from the group consisting of: Na 2 S, K 2 S, CaS and BaS to produce a compound of formula 1':
  • the thiolactone compound 1 is reacted with the amine HNR'R 2 in the presence of an organic acid to produce compound 5.
  • organic acids include formic acid, acetic acid and propionic acid. Most preferably, the reaction is conducted in the presence of acetic acid.
  • compound 4' After the conversion of compound 4' to compound 1', the latter is combined with ammonia or a primary or secondary amine to form compounds of formula 5', which can be deprotected to give compound 6' or salt thereof.
  • solvents such as C,_ 5 alcohols, C j . 3 alkanoic acids, toluene, acetonitrile, ethyl acetate and others may be added to improve crystallization, or otherwise facilitate isolation.
  • addition of a trialkyl or triaryl phosphine, e.g., tri-n-butylphosphine, at this stage may be useful in reducing the formation of disulfides corresponding to compound 6' and/or improving the rejection of other impurities.
  • HNR*R 2 wherein R 1 and/or R 2 represent H, aryl or heteroaryl react with compound 1 upon slight heating. Generally, the reaction proceeds from about RT to about 100°C over a few minutes to several hours.
  • the acid that is used to convert compound 5' to compound 6' can be varied within wide limits.
  • concentrated HCl can be used and is preferred.
  • the invention described herein can be conducted in essentially a single reaction vessel, thus allowing for economical production of compounds 6' from compound 2.
  • the mesylate mixed anhydride was formed according to WO 97/06154 published on February 20, 1997, incorporated herein by reference, and stirred with cooling at -15°C for 15 min.
  • Example One Part B
  • the compounds of column one are reacted with methanesulfonyl chloride to produce the compounds in column two.
  • Example Three Using the procedures set forth in Example Three, the compounds of column one are reacted with the amine in column two to produce the compounds in column three.
  • Tri-n-butylphosphine may be added.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne un procédé de synthétisation d'un composé de formule (1). Un composé de formule (2) est mis à réagir tout d'abord avec un chlorure diphénylphosphinique, afin d'activer le groupe acide carboxylique, puis avec un chlorure méthanesufonyle, afin de produire un composé de formule (4). Ce composé de formule (4) est ensuite mis à réagir avec une source de sulfure d'un métal de groupe II dans de l'eau, afin de produire un composé de formule (1).
PCT/US1998/013738 1997-07-09 1998-07-02 Procede de synthetisation d'intermediaires de carbapenem a chaine laterale Ceased WO1999002531A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU82821/98A AU731586B2 (en) 1997-07-09 1998-07-02 Process for synthesizing carbapenem side chain intermediates
CA002294342A CA2294342C (fr) 1997-07-09 1998-07-02 Procede de synthetisation d'intermediaires de carbapenem a chaine laterale
JP50875599A JP2002504156A (ja) 1997-07-09 1998-07-02 カルバペネム側鎖中間体の合成プロセス
EP98933069A EP1019411A4 (fr) 1997-07-09 1998-07-02 Procede de synthetisation d'intermediaires de carbapenem a chaine laterale

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5203297P 1997-07-09 1997-07-09
US60/052,032 1997-07-09
GBGB9810184.3A GB9810184D0 (en) 1998-05-13 1998-05-13 Process for synthisizing carbapenem side chain intermediates
GB9810184.3 1998-05-13

Publications (1)

Publication Number Publication Date
WO1999002531A1 true WO1999002531A1 (fr) 1999-01-21

Family

ID=26313663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/013738 Ceased WO1999002531A1 (fr) 1997-07-09 1998-07-02 Procede de synthetisation d'intermediaires de carbapenem a chaine laterale

Country Status (5)

Country Link
EP (1) EP1019411A4 (fr)
JP (1) JP2002504156A (fr)
AU (1) AU731586B2 (fr)
CA (1) CA2294342C (fr)
WO (1) WO1999002531A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064684A1 (fr) * 2000-03-01 2001-09-07 Merck & Co., Inc. Formes cristallines d'intermediaires a chaines laterales pour des antibiotiques
US7091363B2 (en) * 2000-11-20 2006-08-15 Sankyo Company, Limited Compounds for the preparation of carbapenem-type antibacterial agents
WO2006020573A3 (fr) * 2004-08-11 2009-04-16 Donald L Barbeau Composes pharmaceutiques non cardiotoxiques
EP0998457A4 (fr) * 1997-07-10 2010-03-10 Formes cristallines d'intermediaires a chaine laterale antibiotiques
WO2010073706A1 (fr) * 2008-12-25 2010-07-01 株式会社カネカ Procédé de production amélioré d'un intermédiaire pour chaîne latérale de carbapénème
CN106565579A (zh) * 2016-06-26 2017-04-19 宁夏海诚电化信息科技有限公司 一种尔它培南侧链生产工艺
CN117304203A (zh) * 2023-09-28 2023-12-29 郑州原理生物科技有限公司 一种美罗培南侧链中间体硫醇内酯的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340738A (en) * 1979-06-21 1982-07-20 Janssen Pharmaceutica, N.V. 2,3-Dihydro-imidazo[2,1-b]benzothiazoles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU644008B2 (en) * 1990-08-10 1993-12-02 Sumitomo Pharmaceuticals Company, Limited Beta-lactam compounds, and their production and use
JP3091297B2 (ja) * 1992-01-10 2000-09-25 住友製薬株式会社 ピロリジン誘導体およびその製造方法
CA2227696C (fr) * 1995-08-04 2003-09-23 Merck & Co., Inc. Procede de synthese de produits intermediaires de chaines laterales de carbapenem

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340738A (en) * 1979-06-21 1982-07-20 Janssen Pharmaceutica, N.V. 2,3-Dihydro-imidazo[2,1-b]benzothiazoles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1019411A4 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0998457A4 (fr) * 1997-07-10 2010-03-10 Formes cristallines d'intermediaires a chaine laterale antibiotiques
WO2001064684A1 (fr) * 2000-03-01 2001-09-07 Merck & Co., Inc. Formes cristallines d'intermediaires a chaines laterales pour des antibiotiques
US7091363B2 (en) * 2000-11-20 2006-08-15 Sankyo Company, Limited Compounds for the preparation of carbapenem-type antibacterial agents
WO2006020573A3 (fr) * 2004-08-11 2009-04-16 Donald L Barbeau Composes pharmaceutiques non cardiotoxiques
US8088918B2 (en) 2004-08-11 2012-01-03 Williamsburg Holdings Llc Noncardiotoxic pharmaceutical compounds
WO2010073706A1 (fr) * 2008-12-25 2010-07-01 株式会社カネカ Procédé de production amélioré d'un intermédiaire pour chaîne latérale de carbapénème
CN106565579A (zh) * 2016-06-26 2017-04-19 宁夏海诚电化信息科技有限公司 一种尔它培南侧链生产工艺
CN117304203A (zh) * 2023-09-28 2023-12-29 郑州原理生物科技有限公司 一种美罗培南侧链中间体硫醇内酯的制备方法

Also Published As

Publication number Publication date
EP1019411A1 (fr) 2000-07-19
AU8282198A (en) 1999-02-08
AU731586B2 (en) 2001-04-05
CA2294342C (fr) 2006-03-14
CA2294342A1 (fr) 1999-01-21
EP1019411A4 (fr) 2003-08-13
JP2002504156A (ja) 2002-02-05

Similar Documents

Publication Publication Date Title
US4631150A (en) Process for the preparation of penems
KR20010086058A (ko) 광범위한 항균 스펙트럼을 갖는이미다조[4,5-ｂ]피리디늄메틸-함유 세펨 화합물
SU856388A3 (ru) Способ получени ненасыщенных производных 7-ациламидо-3-цефем-4-карбоновой кислоты или их сложных эфиров или их солей с щелочными металлами
CA2294342C (fr) Procede de synthetisation d'intermediaires de carbapenem a chaine laterale
CA2657930A1 (fr) Synthese du (2s,5r)-5-ethynyl-1-{n-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile
EP0842166B1 (fr) Procede de synthese de produits intermediaires de chaines laterales de carbapenem
US6063931A (en) Process for synthesizing carbapenem side chain intermediates
EP0557122B1 (fr) Méthode de production de sulphamide
JPH08193076A (ja) Ｎ−アシル助剤を合成する方法
US6060607A (en) Process for synthesizing carbapenem side chain intermediates
KR950013578B1 (ko) 신규 티아(디아)졸 초산의 반응성 티오포스페이트 유도체 및 그의 제조방법
US5648501A (en) Process for synthesizing carbapenem side chain intermediates
GB2257703A (en) Acylation of 7 - amino-cephems
US5721368A (en) Process for synthesizing carbapenem side chain intermediates
KR101059339B1 (ko) 경구 투여용 카르바페넴 화합물의 제조 방법
PL145176B1 (en) Process for preparing derivatives of penemo-2-carboxylic-3-acid
US4841043A (en) Stereoselective synthesis of 1-β-alkyl carbapenem antibiotic intermediates
AU661192B2 (en) 4-substituted alkyl carbapenem antibiotics
JP2696807B2 (ja) カルバペネム誘導体の製法
KR950010083B1 (ko) 세팔로스포린 유도체의 제조방법
WO1991017995A1 (fr) Nouveaux dithiocarbamates de peneme, leur utilisation et procedes de production
KR100650207B1 (ko) 글루타릴 7-아미노-3-비닐-세팔로스포란산 유도체와 이의 제조방법
US20060281918A1 (en) Resolution of enantiomeric mixtures of beta-lactams
IE880488L (en) Benzoindazoles
JPS63310890A (ja) ６−アミノ置換−１−メチルカルバペナム誘導体

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GW HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2294342

Country of ref document: CA

Ref country code: CA

Ref document number: 2294342

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998933069

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 82821/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998933069

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 82821/98

Country of ref document: AU